Literature DB >> 6362864

Current condition and prognosis of tumor immunotherapy: a second opinion.

M J Mastrangelo, D Berd, H C Maguire.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1984        PMID： 6362864

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN： 0361-5960


× No keyword cloud information.
  4 in total

1.  Growth-stimulating phase of macrophage response to activation: the phenomenon and its implications for tumour growth and immunotherapy.

Authors:  V B Okulov; B O Voytenkov; A G Ushmorov; N D Polischuk; S A Gromov
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

2.  Emergence of a dominant cytotoxic T lymphocyte antitumor effector from tumor-infiltrating cells in the anterior chamber of the eye.

Authors:  T L Knisely; J Y Niederkorn
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

3.  Detection of circulating antibodies against c-myc protein in cancer patient sera.

Authors:  K Ben-Mahrez; D Thierry; I Sorokine; A Danna-Muller; M Kohiyama
Journal:  Br J Cancer       Date:  1988-06       Impact factor: 7.640

4.  Augmentation of anti-tumor immunity in low-responder mice by various biological response modifiers: analysis of effector mechanism.

Authors:  T Toko; S Fujimoto
Journal:  Jpn J Cancer Res       Date:  1989-12
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.